Metro

Legislators push effort on prostate cancer care

Chairman of the Senate Ways and Means Committee Stephen Brewer is a prostate cancer survivor.

AP/File 2007

Chairman of the Senate Ways and Means Committee Stephen Brewer is a prostate cancer survivor.

Three members of the Massachusetts Legislature are speaking out about their own battles against prostate cancer in an effort to elevate awareness of the threat and screening options.

The chairman of the Senate Ways and Means Committee, Stephen Brewer; Senator Kenneth Donnelly; and the vice chairman of the House Ways and Means Committee, Stephen Kulik, are all prostate cancer survivors and support creation of a statewide program for prostate cancer education and awareness.

Advertisement

Among the practices Brewer and the others want to promote is nonintrusive imaging scans for the prostate, which he called the male equivalent to a mammogram screening for breast cancer in women. “It is more predominant than breast cancer, but yet the research and the remediation dollars are less than breast cancer,” Brewer said. “And so the term for this is ‘manograms’ instead of mammograms, to have the analysis of your own prostate.”

According to the prostate cancer advocacy nonprofit group AdMeTech, the most common current methods to diagnose the cancer are blood tests and traditional biopsies.

Get Fast Forward in your inbox:
Forget yesterday's news. Get what you need today in this early-morning email.
Thank you for signing up! Sign up for more newsletters here

The American Cancer Society estimates that prostate cancer will kill 29,480 American men this year, with 233,000 being diagnosed with the disease.

At a breakfast last week hosted by AdMeTech, president Faina Shtern said the state of prostate cancer care “is barbaric.”

“There’s an overwhelming number of unnecessary and failed procedures,” Shtern said. “We are here to change that.”

Advertisement

Lawmakers hope to make Massachusetts a model state for prostate cancer awareness and treatment.

According to AdMeTech, the incidence of the disease is 19 percent higher than that of breast cancer in the state. The fatality rate is 7 percent greater for prostate cancer victims than that of breast cancer patients, the group reports.

Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.